Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment
© Münter et al; licensee BioMed Central Ltd. 2006
Received: 20 March 2006
Accepted: 06 June 2006
Published: 06 June 2006
Presenting the initial clinical results in the treatment of complex shaped adenoid cystic carcinomas (ACC) of the head and neck region by inverse planned stereotactic IMRT.
25 patients with huge ACC in different areas of the head and neck were treated. At the time of radiotherapy two patients already suffered from distant metastases. A complete resection of the tumor was possible in only 4 patients. The remaining patients were incompletely resected (R2: 20; R1: 1). 21 patients received an integrated boost IMRT (IBRT), which allow the use of different single doses for different target volumes in one fraction. All patients were treated after inverse treatment planning and stereotactic target point localization.
The mean folllow-up was 22.8 months (91 – 1490 days). According to Kaplan Meier the three year overall survival rate was 72%. 4 patients died caused by a systemic progression of the disease. The three-year recurrence free survival was according to Kaplan Meier in this group of patients 38%. 3 patients developed an in-field recurrence and 3 patient showed a metastasis in an adjacent lymph node of the head and neck region. One patient with an in-field recurrence and a patient with the lymph node recurrence could be re-treated by radiotherapy. Both patients are now controlled. Acute side effects >Grade II did only appear so far in a small number of patients.
The inverse planned stereotactic IMRT is feasible in the treatment of ACC. By using IMRT, high control rates and low side effects could by achieved. Further evaluation concerning the long term follow-up is needed. Due to the technical advantage of IMRT this treatment modality should be used if a particle therapy is not available.
Adenoid cystic carcinomas of the head and neck are a unique kind of tumour deriving from cells of the major and minor salivary glands, they account for 25% of all malignant salivary gland tumours in different series. Although ACCs are the most common histological type of tumours in the minor salivary glands with a total of 55%  they account for only about 10–15% of all parotid gland malignancies. ACCs can be shown to be unique for various reasons: first of all, these tumours often show a protracted natural history. When compared to other malignancies, a prolonged survival of patients with ACCs is possible even in case of local recurrence or distant metastases. Second, ACCs characteristically exhibit a locally aggressive growth pattern with a unique tendency to nervous tissue invasion. They might also spread greater distances from the primary location by growing along the nerve sheaths. In some cases, skip involvement can be seen along the perineural space.
Hence, treatment of adenoid cystic carcinomas of the head and neck presents a serious therapeutic challenge in most cases. Surgical treatment is limited by the tumours' growth pattern mentioned above. Despite complete gross tumor resection due to paraneural spread in some cases surgery is not radical. However, surgery is still the preferred treatment of ACCs but complete resection might not always be possible or feasible if too many normal structures are injured.
So radiation therapy often is an important part in the treatment, either as postoperative therapy or as definite treatment if a complete resection of the tumour is not possible [2, 3]. However, the radiotherapeutic approach is also similarly challenging due to numerous radiosensitive structures in the head and neck region as doses ranging between 60 and 70 Gy should be achieved in macroscopic tumours. At these total doses normal tissue reactions in curable disease is frequent and should be reduced by introducing new planning technologies. Recent advances in radiation oncology and treatment planning led to the implementation of inverse planned intensity modulated radiation therapy (IMRT). This treatment technique allows the optimisation of target volume coverage while allowing to reduce the dose to surrounding organs at risk. Therefore an increased total dose could be achieved with a better coverage of the target volume. Initial results using IMRT show an improvement of local tumour control rates and toxicity profiles in patients with tumours of the head and neck [4–6]. The aim of this publication is to present the inverse planned IMRT treatment technique, initial clinical results, and toxicities in patients with complex shaped ACCs of the head and neck.
Localization of the tumor
Number of patients
Base of skull/Sinus maxillaris
Adequate immobilisation is a crucial prerequisite for obtaining the high accuracy needed for stereotactically guided IMRT and therefore an important part of the definition of IMRT at our institution. Hence, a customised individual immobilisation device depending on the tumour location was created for each individual patient. For treatment of lesions in the brain or base of skull the patient was positioned supine with an individually made mask which, at the German Cancer Research Centre (dkfz), consists of Scotch Cast material wrapped around the head of the patient. Serial 3 mm CT slices of the of the whole treatment area plus a superior margin of 5 cm and an adequate inferior margin to cover the neck lymph nodes level I-III were acquired using a stereotactic head frame. Contrast agent was administered according to our in-house protocol. Additionally, a contrast MRI scan was performed of the primary tumour area with the patient also positioned in the individual mask and using a stereotactic head frame.
Target volumes and organs at risk were defined slice by slice on the treatment planning CTs using the 3D-conformal radiotherapy planning system VIRTUOS which was developed at the dkfz. An image fusion of the treatment planning CT and the MRI scan was performed for a more accurate definition of the target volume and critical normal structures. Image registration was done stereotactically.
The CTV I was defined as the visible tumour volume in the imaging studies plus a margin of 2 mm. For patient treated after a complete resection the area of the tumours visualized by preoperative scans was defined as CTV I. CTV II was drawn around the CTV I with a generous margin depending on the anatomical relationship of adjacent structures and potential microscopic spread. Areas with potential subclinical disease, in particular the neurovascular sheaths in ACCs, were also included in the CTV II. The ipsilateral lymph node level direct adjacent to the primary tumor region was furthermore defined as CTV II in all cases. Additional lymph nodes or lymph node level highly suspicious for tumor in CT or MRI or after biopsy were defined as CTV II This was necessary for two patients. One of these two patients received treatment of bilateral lymph node levels II and III. Volume of CTV I ranged between 50 to 896 cm3 (Mean: 257 cm3) and for CTV II between 233 and 950 cm3 (Mean: 433 cm3). Surrounding organs at risk were also contoured slice by slice with special regard to the spinal cord, brainstem, optical nerve, chiasm, and the temporomandibular joint.
KonRad inverse planning system developed at the dkfz and now commercially available at Siemens Medical Solutions was used for inverse treatment planning and was linked to VIRTUOS for 3D dose calculation and visualisation. No additional margins were defined around the target volumes in the inverse treatment planning program.
In order to start the optimisation process in KonRad, the user needs to define maximum and minimum dose constraints on both the target volumes and the organs at risk. Moreover, penalties defining the relative importance of the individual constraints have to be specified. Based on these constraints and penalties, KonRad then uses an iterative optimisation algorithm (gradient technique) in order to improve the 3D dose distribution by minimising the objective function. In addition to the dose specifications, the user is also able to select the couch, gantry, and collimator angles as well as the number of intensity levels representing the complexity of beam modulation in the KonRad planning system. On optimisation, treatment plans using 5, 7, or 9 equidistant gantry angles, coplanar or non-coplanar couch position were evaluated in order to define the beam arrangement with the best target volume coverage and normal tissue sparing. 4 to 8 non-zero intensity levels were used to define the fluence map. An integrated boost radiotherapy (IBRT) was optionally used for patients with macroscopic tumors . This IMRT technique allows the treatment of various target volumes simultaneously with various doses per fraction and in turn allows escalation of the individual dose per fraction to the CTV I.
The total doses for all target volumes were prescribed to the median of the target volumes with 50% of the individual target volume receiving 100% of the total dose. At our institution, the dose of all IMRT treatment plans is prescribed to the median.
The maximum dose to the cervical spinal cord was limited to 45 Gy while the maximum dose to the brainstem, the optic nerve and chiasm was limited to 54 Gy. For the remaining organs at risk the dose thresholds specified by  were accepted. The target point of the IMRT treatment was defined stereotactically and treatment was performed on a step-and-shoot approach using a linear accelerator with photon energies of 6 MV and 15 MV and integrated multi-leaf collimator (MLC) (Siemens Medical Solutions).
The patients were seen regularly for clinical examination during and after radiation therapy. Acute toxicity was specified according to the Common Toxicity Criteria (CTC) during treatment and 3 months afterwards. After 3 months, the RTOG/EORTC criteria for radiation late-effects were used for evaluation. The first MRI scan of the area treated was performed 6 weeks after radiation therapy was completed. For the first 2 years after radiation therapy, patients were followed up in intervals of 3 to 6 months including clinical examination and MRI scans. Depending on clinical and radiological findings the period between individual follow-ups was increased after the second year. The measurement of follow-up was initiated with the beginning of radiation therapy. The Kaplan-Meier method was applied to analysis of overall survival, disease-free survival, and control rate.
Integrated boost IMRT (IBRT) was performed in 21 patients. The median total dose delivered to the CTV I was 66 Gy (range: 58 – 70.4 Gy) and the median dose per fraction to the CTV I was 2 Gy (range 1.8 – 2.2 Gy). Only in one patient with an macroscopic ACC the dose of the CTV I was lower than 60 Gy due to a diffuse infiltrating tumor with a close relationship to the myelon and the brainstem. Using the same number of fractions, the median total dose to the CTV II was 60 Gy (range 56 – 64.2 Gy) and the median dose per fraction was 1.9 Gy (1.7 – 2.0 Gy). In only 2 patients a non-coplanar beam set-up was used. The median number of beams applied was 7 (range 5 – 9). The total number of sub-segments for the step-and-shoot IMRT approach ranged between 48 and 100 (median 75). Approximately 6 segments per minute could be applied by the system used. Therefore, the absolute treatment time ranged between 8 and 16.7 minutes (median: 12.5 minutes). For rotation of the gantry to the next treatment position approximately 8 sec. were needed. By two minutes increased the treatment time if a movement of the table for non-coplanar treatment was necessary. Additional 5 minutes were needed to position the patient in the mask and for target point localisation and adjustment.
Treatment had to be interrupted in only one patient for no longer than 2 days due to acute side-effects. Severe acute side-effects were mucositis grade III, seen in 5 patients (20%), and mucositis grade II, seen in 11 patients (44%). 1 patient (4%) showed a grade III skin reaction while 11 patients (44%) showed a grade II skin reaction. In addition, a slight hair loss, nausea, inner ear effusion, and xerostomia occurred during radiotherapy. Apart from the xerostomia, these symptoms had completely disappeared 3 months after completion of radiotherapy. Xerostomia grade II has so far been the only severe late-effect observed in 5 patients.
The data presented are able to support that IMRT is a safe and feasible modality in the treatment of complex-shaped ACCs in the head and neck. By using IMRT, high doses in the GTV and PTV can be achieved together with an excellent normal tissue sparing, especially bearing in mind the dose-response relationship for ACCs described by various authors. Garden et al.  could demonstrate significant differences with respect to local control rates between patients treated with doses of less than 56 Gy and patients treated with more than 56 Gy. Hence, these authors are recommending a dose of 60 Gy to the tumour bed and 66 Gy to the tumour bed in patients with positive margins. Harrison at al.  could show a comparable effect using doses of at least 57.5 Gy compared with lower doses for histologically different major salivary gland tumours. The authors found a reduced 10-year local control rate with 53% in patients treated with lower doses compared to 72% in patients treated with more than 57.5 Gy. Using high doses to the CTV I in this study, an in-field recurrence only occurred in 3 patients so far. Furthermore, IMRT offers the advantage of treating various target volumes with different doses per fraction. This results in a reduced overall treatment time and increased doses per fraction to areas with macroscopic disease. IBRT hence does also have advantages especially with respect to radiobiology. In this study, 21 out of the 25 patients were treated with IBRT showing no increase in side-effects when compared with the four patients treated with a conventional IMRT regimen. All in all, acute and late side-effects were negligible in this study so far. No grade IV toxicity was seen, and only 20% of the patients developed a grade III toxicity of the mucosa. These results are comparable to the results from a group of patients treated with photons in the study of Huber et al. . This study demonstrated similar acute side-effects for patients treated with photons. Nevertheless, patients treated with neutrons showed increased late-effects when compared to patients receiving photon radiotherapy.
Indications have to be defined for IMRT in the treatment of ACCs when compared to radiotherapy regimen using high relative biological effectiveness (RBE) beams. With respect to high-RBE beams, the longest experience exists using neutrons. The use of neutrons compared to photons shows an advantage in most studies. The only prospective randomised trial comparing neutrons and photons  revealed an increased 2-year-survival rate with 62% in patients treated with neutrons compared to 25% patients treated with photons (p < 0.005). Additionally, the loco-regional control rates at two years were 67% for neutrons and 17% for photons (p = 0.10). The final report of this study with a follow-up of ten years and 25 patients supports the initially published results demonstrating significantly higher control rates in the treatment with neutrons without improvement of overall survival .
Douglas et al.  published a huge trial of 151 patients with non-resectable ACC treated with neutrons. The 5-year-actuarial local control rate was 57% and the actuarial overall survival was 72%. A retrospective trial by Huber et al.  compared the results of our institution in the treatment of ACCs to treatments with neutrons alone, with a combination of neutrons and photons, and photons alone. The local control rates were 75% for neutrons and 32% for the combined therapy as well as photons alone. No differences could be observed with respect to the overall survival in this study. Promising results in reduction of side effects and improvement of outcome were presented by our group when combining IMRT and carbon ion therapy as a boost treatment. In this prospective study published by Schulz-Ertner et al.  there was no higher late toxicity than CTC grade II so far. Additionally, the 3-year actuarial overall survival rate was 83.3%. Only 3 patients had a loco-regional recurrence at a median follow-up of 12 months.
The data presented in our study shows comparable results to most studies using photon beams for the treatment of ACCs. IBRT and IMRT with the tested dose concept is feasible and results in a promising clinical outcome justifying further investigations. Furthermore describes the IBRT concept a promising approach to escalate the dose further while reducing the treatment time.
A prospective study investigating the possible advantages of IBRT plus carbon ion boost compared to IBRT alone needs to be performed. Nevertheless, long-term results in treatment of ACCs remain disappointing even applying highly sophisticated radio-oncological treatment techniques due to the high number of distant metastases. Hence, future therapy of ACCs should also strongly focus on improvement systemic treatment of this disease.
- Tran L, Sidrys J, Sadeghi A, Ellerbroek N, Hanson D, Parker RG: Salivary gland tumors of the oral cavity. Int J Radiat Oncol Biol Phys 1990,18(2):413-417.View ArticlePubMed
- Guerney TA, Eisele DW, Weinberg V, Shin E, Lee N: Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 2005, 115: 1278-1282. 10.1097/01.MLG.0000165381.64157.ADView Article
- Silvermann DA, Carlson TP, Khuntia D, Bergstrom RT, Saxton J, Esclamado RM: Role of postoperative radiation therapy in adenoid cystic carcinoma of the head and neck . Laryngoscope 2004, 114: 1194-1199. 10.1097/00005537-200407000-00012View Article
- Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK: Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002,53(1):12-22. 10.1016/S0360-3016(02)02724-4View ArticlePubMed
- Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM: Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003,57(1):49-60. 10.1016/S0360-3016(03)00405-XView ArticlePubMed
- Munter MW, Thilmann C, Hof H, Didinger B, Rhein B, Nill S, Schlegel W, Wannenmacher M, Debus J: Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol 2003,66(3):313-321. 10.1016/S0167-8140(03)00021-5View ArticlePubMed
- Thilmann C, Zabel A, Grosser KH, Hoess A, Wannenmacher M, Debus J: Intensity-modulated radiotherapy with an integrated boost to the macroscopic tumor volume in the treatment of high-grade gliomas. Int J Cancer 2001,96(6):341-349. 10.1002/ijc.1042View ArticlePubMed
- Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991,21(1):109-122.View ArticlePubMed
- Garden AS, Weber RS, Morrison WH, Ang KK, Peters LJ: The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995,32(3):619-626. 10.1016/0360-3016(95)00122-FView ArticlePubMed
- Harrison LB, Armstrong JG, Spiro RH, Fass DE, Strong EW: Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol 1990,45(1):52-55.View ArticlePubMed
- Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, Engenhart-Cabillic R: Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 2001,59(2):161-167. 10.1016/S0167-8140(00)00273-5View ArticlePubMed
- Griffin TW, Krall JM, Russell KJ, Peters LJ, Thomas FJ, Hendrickson FR, Laramore GE: Fast neutron irradiation of locally advanced prostate cancer. Semin Oncol 1988,15(4):359-365.PubMed
- Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, Maor MH, Davis LW: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 1993,27(2):235-240.View ArticlePubMed
- Douglas JG, Laramore GE, Austin-Seymour M, Koh W, Stelzer K, Griffin TW: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 2000,46(3):551-557. 10.1016/S0360-3016(99)00445-9View ArticlePubMed
- Schulz-Ertner D, Nikoghosyan A, Jakel O, Haberer T, Kraft G, Scholz M, Wannenmacher M, Debus J: Feasibility and toxicity of combined photon and carbon ion radiotherapy for locally advanced adenoid cystic carcinomas. Int J Radiat Oncol Biol Phys 2003,56(2):391-398. 10.1016/S0360-3016(02)04511-XView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.